IOL Chemicals and Pharmaceuticals Stock Price Rises Over 12% on Strong Q2 Results

Ludhiana, November 12, 2025: IOL Chemicals and Pharmaceuticals Ltd shares saw a rally during the early trading hours on Wednesday morning. The stock surged by 12.03% and was trading at ₹99.48 at 10:30 AM. This surge in the share of IOL Chemicals came following the strong financial performance reported by the company for the second quarter of FY26.

Q2 FY26 Financial Performance (Standalone)

The revenue from operations reached ₹567.50 crore, showing a 7.9% year-on-year growth. In addition, the EBITDA went up to ₹64 crore, which is 33.3% more than the same quarter of the previous year. The PAT also made a decent jump of 56.70% and reached ₹30.00 crore, with the margin improving by 162 basis points to 5.2%.

For the half-year (H1 FY26), revenue grew 8.9% YoY to ₹1,119.2 crore, while PAT rose 31% YoY to ₹64 crore, driven by improved operational efficiencies and a stronger product mix.

Segment Performance

In the pharmaceuticals segment, the revenue increased to ₹665.7 crore, which was supported by strong traction in non-Ibuprofen APIs. In the chemicals segment, the revenue increased to ₹453.5 crore, which reflects stable demand recovery, even though the sector faced pricing pressure.

Operational & Strategic Highlights

The company was awarded with EDQM’s Certificate of Suitability for Pantoprazole Sodium Sesquihydrate Process-III, which enables export to the EU and CEP-compliant nations. It also incorporated Pharmaxis UK Limited in October 2025, which expands both pharma and chemical operations globally.

Market Snapshot 

At 10:30 AM, the stock traded at ₹99.48 (12.03% higher than the previous day’s closing). The stock opened strong and soon reached the day’s high of ₹99.85 and has moved sideways since then. The company’s PE ratio is 24.80 compared to the industrial average of 33.73. After today’s surge, the stock has moved up by more than 52% in the past six-month period.

The company is a leading manufacturer of APIs (Active Pharmaceutical Ingredients) and speciality chemicals. It is also one of the largest producers of painkiller Ibuprofen and enjoys a 30% global market share in manufacturing the medicine. The company was founded in 1986 and is headquartered in Ludhiana. The company is also one of the largest producers of Iso Butyl Benzene (IBB) and Ethyl Acetate. Besides the Indian markets, it services global clients in the US, UK, China and Germany while being supported by regulatory approvals.

REF: https://nsearchives.nseindia.com/corporate/IOLCP_11112025180908_Press_Release_11112025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations